Latest News

Opinion: Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

One of the many things I’ve learned during four decades of doing research on Alzheimer’s disease is that the work always brings surprises. Biogen’s announcement on Tuesday about its experimental Alzheimer’s drug, aducanumab, was a big one.

Back in March, the company stopped two large Phase 3 clinical trials of the drug after futility analyses showed that aducanumab was unlikely to provide a benefit compared to placebo.

Read the rest…

Source link

Related posts

HLTH conference will spotlight voice-driven tech applications in healthcare [Sponsored]


Ceria Entrapped Palladium Novel Composites for Hydrogen Oxidation Reaction in Alkaline Medium


Yearly Flu Shot for Kids Isn't Overkill


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World